BIGG

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Miller, R. E; Leary, A; Scott, C. L; Serra, V; Lord , C. J; Bowtell, D; Chang, D. K; Garsed, D. W; Jonkers, J; Ledermann, J. A; Nik-Zainal, S; Ray-Coquard, I; Shah, S. P; Matias-Guiu, X; Swisher, E. M; Yates, L. R.

The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group identified that there is currently uncertainty within the oncology community surrounding the different methods for HRD testing in HGSC. To address this, a collaborative project was launched with a...

Recombinación Homóloga/genética, Inhibidores de Poli(ADP-Ribosa) Polimerasas/uso terapéutico, Biomarcadores, Neoplasias de los Genitales Femeninos/diagnóstico, Mutación de Línea Germinal/genética

Texto completo

Guideline No. 404: initial investigation and management of benign ovarian masses

To provide recommendations for a systematic approach to the initial investigation and management of a benign ovarian mass and facilitate patient referral to a gynaecologic oncologist for management....